Guggenheim Capital’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $44.8M | Sell |
100,386
-655
| -0.6% | -$305K | 0.35% | 55 |
|
|
2025
Q4 | $45.8M | Sell |
101,041
-2,084
| -2% | -$898K | 0.33% | 61 |
|
|
2025
Q3 | $40.4M | Buy |
103,125
+1,905
| +2% | +$796K | 0.29% | 67 |
|
|
2025
Q2 | $45.1M | Sell |
101,220
-783
| -0.8% | -$361K | 0.36% | 58 |
|
|
2025
Q1 | $49.5M | Sell |
102,003
-33,692
| -25% | -$15.7M | 0.45% | 44 |
|
|
2024
Q4 | $54.6M | Sell |
135,695
-3,596
| -3% | -$1.67M | 0.44% | 40 |
|
|
2024
Q3 | $64.8M | Sell |
139,291
-20,396
| -13% | -$9.8M | 0.45% | 36 |
|
|
2024
Q2 | $74.8M | Sell |
159,687
-6,014
| -4% | -$2.61M | 0.53% | 24 |
|
|
2024
Q1 | $69.3M | Sell |
165,701
-5,961
| -3% | -$2.52M | 0.49% | 25 |
|
|
2023
Q4 | $69.8M | Buy |
171,662
+9,784
| +6% | +$3.61M | 0.53% | 23 |
|
|
2023
Q3 | $56.3M | Buy |
161,878
+3,146
| +2% | +$1.1M | 0.48% | 28 |
|
|
2023
Q2 | $55.9M | Sell |
158,732
-4,115
| -3% | -$1.39M | 0.44% | 30 |
|
|
2023
Q1 | $51.3M | Sell |
162,847
-6,112
| -4% | -$1.83M | 0.43% | 36 |
|
|
2022
Q4 | $48.8M | Sell |
168,959
-6,140
| -4% | -$1.87M | 0.43% | 35 |
|
|
2022
Q3 | $50.7M | Sell |
175,099
-20,047
| -10% | -$5.77M | 0.46% | 26 |
|
|
2022
Q2 | $55M | Sell |
195,146
-25,465
| -12% | -$6.82M | 0.43% | 29 |
|
|
2022
Q1 | $57.6M | Buy |
220,611
+8,939
| +4% | +$2.12M | 0.35% | 39 |
|
|
2021
Q4 | $46.5M | Buy |
211,672
+4,577
| +2% | +$890K | 0.24% | 74 |
|
|
2021
Q3 | $37.6M | Sell |
207,095
-9,157
| -4% | -$1.79M | 0.23% | 77 |
|
|
2021
Q2 | $43.6M | Buy |
216,252
+12,343
| +6% | +$2.58M | 0.26% | 63 |
|
|
2021
Q1 | $43.8M | Sell |
203,909
-5,881
| -3% | -$1.29M | 0.29% | 57 |
|
|
2020
Q4 | $49.6M | Buy |
209,790
+17,699
| +9% | +$4.06M | 0.31% | 44 |
|
|
2020
Q3 | $52.3M | Sell |
192,091
-3,079
| -2% | -$849K | 0.38% | 33 |
|
|
2020
Q2 | $56.7M | Buy |
195,170
+3,640
| +2% | +$987K | 0.44% | 24 |
|
|
2020
Q1 | $45.6M | Sell |
191,530
-21,965
| -10% | -$5.04M | 0.46% | 25 |
|
|
2019
Q4 | $46.7M | Sell |
213,495
-20,187
| -9% | -$4.09M | 0.35% | 42 |
|
|
2019
Q3 | $39.6M | Sell |
233,682
-2,694
| -1% | -$477K | 0.32% | 48 |
|
|
2019
Q2 | $43.3M | Sell |
236,376
-10,327
| -4% | -$1.81M | 0.35% | 42 |
|
|
2019
Q1 | $45.4M | Buy |
246,703
+12,245
| +5% | +$2.26M | 0.37% | 35 |
|
|
2018
Q4 | $38.9M | Sell |
234,458
-24,893
| -10% | -$4.31M | 0.33% | 37 |
|
|
2018
Q3 | $50M | Sell |
259,351
-3,346
| -1% | -$596K | 0.33% | 39 |
|
|
2018
Q2 | $44.6M | Sell |
262,697
-473,152
| -64% | -$73.3M | 0.3% | 41 |
|
|
2018
Q1 | $120M | Sell |
735,849
-68,978
| -9% | -$11.3M | 0.29% | 25 |
|
|
2017
Q4 | $121M | Buy |
804,827
+376,093
| +88% | +$55.7M | 0.29% | 26 |
|
|
2017
Q3 | $65.2M | Sell |
428,734
-68,817
| -14% | -$10.4M | 0.15% | 148 |
|
|
2017
Q2 | $64.1M | Sell |
497,551
-72,719
| -13% | -$8.75M | 0.17% | 150 |
|
|
2017
Q1 | $62.4M | Sell |
570,270
-44,889
| -7% | -$3.95M | 0.17% | 150 |
|
|
2016
Q4 | $45.3M | Buy |
615,159
+114,038
| +23% | +$9.28M | 0.13% | 280 |
|
|
2016
Q3 | $43.7M | Sell |
501,121
-1,949
| -0.4% | -$184K | 0.14% | 233 |
|
|
2016
Q2 | $43.3M | Sell |
503,070
-14,031
| -3% | -$1.21M | 0.14% | 237 |
|
|
2016
Q1 | $41.1M | Buy |
517,101
+11,785
| +2% | +$1.07M | 0.13% | 235 |
|
|
2015
Q4 | $63.6M | Sell |
505,316
-7,417
| -1% | -$895K | 0.19% | 101 |
|
|
2015
Q3 | $53.4M | Sell |
512,733
-121,983
| -19% | -$15.7M | 0.16% | 123 |
|
|
2015
Q2 | $78.4M | Buy |
634,716
+29,031
| +5% | +$3.66M | 0.19% | 73 |
|
|
2015
Q1 | $71.5M | Buy |
605,685
+90,152
| +17% | +$10.8M | 0.17% | 113 |
|
|
2014
Q4 | $61.2M | Sell |
515,533
-400,094
| -44% | -$45.1M | 0.15% | 143 |
|
|
2014
Q3 | $103M | Buy |
915,627
+31,288
| +4% | +$2.98M | 0.25% | 27 |
|
|
2014
Q2 | $83.7M | Sell |
884,339
-56,286
| -6% | -$3.95M | 0.21% | 58 |
|
|
2014
Q1 | $66.5M | Buy |
940,625
+182,273
| +24% | +$14.4M | 0.19% | 83 |
|
|
2013
Q4 | $56.3M | Buy |
758,352
+67,328
| +10% | +$4.69M | 0.17% | 101 |
|
|
2013
Q3 | $52.4M | Buy |
691,024
+139,449
| +25% | +$11.1M | 0.19% | 77 |
|
|
2013
Q2 | $44.1M | Buy |
+551,575
| New | +$40.6M | 0.19% | 72 |
|
Other funds holding VRTX
VCM
VPM
Guggenheim Capital's VRTX Position: Q1 2026 in Review
Guggenheim Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 0.65% in Q1 2026, selling an estimated $305K and leaving 100,386 shares worth $44.8M. The position accounts for 0.35% of the portfolio, ranked #55.
Guggenheim Capital first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $121M in Q4 2017. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Guggenheim Capital held 100,386 shares of Vertex Pharmaceuticals worth $44.8M as of Q1 2026.
- Guggenheim Capital sold 655 Vertex Pharmaceuticals shares in Q1 2026, an estimated $305K.
- Vertex Pharmaceuticals made up 0.35% of Guggenheim Capital's portfolio in Q1 2026, its #55 holding.
- Guggenheim Capital first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Guggenheim Capital's Vertex Pharmaceuticals position peaked at $121M in Q4 2017.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Guggenheim Capital's 13F filing for Q1 2026, filed 15 May 2026.